Mutations in ASXL1 and/or TET2 Identify a Subset with Worse Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasms

被引：0

作者：

Xu, Mina ^{[1
]}

Thakkar, Devang ^{[2
]}

Panse, Gauri ^{[1
]}

Yan, Jiong ^{[3
,4
]}

Minden, Mark ^{[5
]}

Zandi, Sasan ^{[6
]}

Naresh, Kikkeri ^{[7
]}

Czader, Magdalena ^{[8
]}

Love, Cassandra ^{[2
]}

Happ, Lanie ^{[9
]}

Koff, Jean ^{[10
]}

Jaye, David ^{[11
]}

Michael, Churnetski ^{[10
]}

Arildsen, Mary Ann ^{[12
]}

Juskevicius, Ridas ^{[13
]}

Soliman, Dina ^{[14
]}

Louissaint, Abner ^{[15
]}

Mckinney, Matthew ^{[2
]}

Sojitra, Payal ^{[16
]}

Yin, C. Cameron ^{[17
]}

Ondrejka, Sarah ^{[18
]}

Tse, Eric ^{[19
]}

Dave, Sandeep ^{[2
]}

机构：

[1] Yale Univ, New Haven, CT USA

[2] Duke Univ, Durham, NC USA

[3] Univ Hlth Network, Lab Med Program, Dept Anat Pathol, Toronto, ON, Canada

[4] Univ Toronto, Toronto, ON, Canada

[5] Univ Hlth Network, Toronto, ON, Canada

[6] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[7] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[8] Indiana Univ, Indianapolis, IN USA

[9] Data Driven Biosci, Durham, NC USA

[10] Emory Univ, Atlanta, GA USA

[11] Emory Univ, Sch Med, Atlanta, GA USA

[12] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[13] Pathgroup, Nashville, TN USA

[14] Hamad Med Corp, Doha, Qatar

[15] Massachusetts Gen Hosp, Boston, MA 02114 USA

[16] Univ Med & Dent New Jersey, New Brunswick, NJ USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[18] Cleveland Clin, Cleveland, OH USA

[19] Univ Hong Kong, Pokfulam, Hong Kong, Peoples R China

来源：

LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

1210

引用

页码：S1258 / S1259

页数：2

共 50 条

[31] Persistence of Mutations in Complete Remission Including DNMT3A, TET2 and ASXL1 Mutations Is Associated with Worse Prognosis in Patients with Acute Myeloid Leukemia Treated in ALFA 0702 Study
Hirsch, Pierre
Lambert, Jerome
Bucci, Maxime
Deswarte, Caroline
Lambert, Juliette
Fenwarth, Laurene
Dombret, Herve
Duployez, Nicolas
Preudhomme, Claude
Itzykson, Raphael
Delhommeau, Francois
BLOOD, 2022, 140
[32] The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis
Zhao, Wenxia
Zhang, Conghui
Li, Yiming
Li, Yang
Liu, Yang
Sun, Xiaoyu
Liu, Mingyan
Shao, Rongguang
HEMATOLOGY, 2022, 27 (01) : 367 - 378
[33] New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders
Traina, Fabiola
Jankowska, Ania
Makishima, Hideki
Hsieh, Fred H.
Han, Yingchun
O'Keefe, Christine
Sugimoto, Yuka
Mohan, Sanjay R.
Szpurka, Hadrian
Prince, Courtney
Guinta, Kathryn
Sekeres, Mikkael A.
Kalaycio, Matt
Lichtin, Alan E.
Advani, Anjali S.
Copelan, Edward
Sobecks, Ronald
Maciejewski, Jaroslaw P.
Tiu, Ramon V.
BLOOD, 2010, 116 (21) : 1268 - 1269
[34] Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
Pemmaraju, Naveen
Thomas, Deborah
Kantarjian, Hagop M.
Cortes, Jorge E.
Manning, John T.
Medeiros, L. Jeffrey
O'Brien, Susan
Daver, Naval G.
Nazha, Aziz
Pierce, Sherry A.
Garcia-Manero, Guillermo
Jabbour, Elias J.
Faderl, Stefan
BLOOD, 2012, 120 (21)
[35] Clinical Characteristics, Immunophenotype and Outcomes of Blastic Plasmacytoid Dendritic Cell Neoplasms in a Peruvian Cohort
Duenas, Daniela
Cervantes, Elizabeth
Enriquez, Daniel J.
Flores, Claudio
Barrionuevo, Carlos
Alcarraz, Cindy
Lopez, Lourdes
Quintana, Shirley
Vasquez, Jule F.
Retamozo, Rosario
Vidal, Judith
Saldarriaga, Tatiana
Carrasco-Yalan, Antonio A.
Garcia-Leon, Juan L.
Samanez-Figari, Cesar
BLOOD, 2020, 136
[36] Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations
Oak, Jean S.
Ohgami, Robert S.
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 781 - 782
[37] Zebrafish models of myeloid malignancies produced through tet2 and asxl1 genomic editing
Gjini, Evisa
Mansour, Marc
Sander, Jeffry
He, Shuning
Ko, Myunggon
Zhou, Yi
Rodig, Scott
Joung, Keith
Zon, Leonard
Rao, Anjana
Look, Thomas
CANCER RESEARCH, 2015, 75
[38] TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes
Hu, Jinjun
Xu, Jing
Tian, Tingting
Xie, Juan
Fan, Lifang
Zhu, Guiyang
Xia, Ting
Chen, Xi
Tan, Yanhong
Chen, Xiuhua
Ren, Fanggang
Zhang, Yaofang
Wang, Hongwei
Xu, Zhifang
BLOOD CELLS MOLECULES AND DISEASES, 2019, 74 : 44 - 50
[39] ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
Damaj, Gandhi
Joris, Magalie
Chandesris, Olivia
Hanssens, Katia
Soucie, Erinn
Canioni, Danielle
Kolb, Brigitte
Durieu, Isabelle
Gyan, Emanuel
Livideanu, Cristina
Cheze, Stephane
Diouf, Momar
Garidi, Reda
Georgin-Lavialle, Sophie
Asnafi, Vahid
Lhermitte, Ludovic
Lavigne, Christian
Launay, David
Arock, Michel
Lortholary, Olivier
Dubreuil, Patrice
Hermine, Olivier
PLOS ONE, 2014, 9 (01):
[40] Unlike TET2 and ASXL1, Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2-Mutant Myeloproliferative Neoplasms (MPNs)
How, Joan
Marneth, Anna E.
Kamaz, Baransel
Kim, Chulwoo J.
Neuberg, Donna S.
Ren, Siyang
Wazir, Mohammed
Weeks, Lachelle D.
Stahl, Maximilian
DeAngelo, Daniel J.
Lindsley, Coleman
Luskin, Marlise R.
Hormoz, Sahand
Mullally, Ann
BLOOD, 2023, 142

← 1 2 3 4 5 →